Burford Capital Limited logo
Burford Capital Limited BUR
$ 8.52 -2.46%

Annual report 2020
added 12-16-2023

report update icon

Burford Capital Limited Total Assets 2011-2026 | BUR

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Burford Capital Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 3.11 B 3.04 B 2.32 B 1.5 B 968 M 594 M 533 M 376 M 345 M 322 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.11 B 322 M 1.31 B

Quarterly Total Assets Burford Capital Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - 3.11 B - - - 3.04 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
3.11 B 3.04 B 3.08 B

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
16.1 M $ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
514 M $ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
13.6 M - -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
5.74 M - -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
1.08 B $ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
1.36 B $ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
105 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
690 M $ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
936 M $ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
1.83 M - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
325 M - -4.8 % $ 255 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
435 M - - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
337 M - - $ 789 M usaUSA
Certara Certara
CERT
1.56 B $ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
7.47 M - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
35 M - -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
473 M - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
78.8 M - - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
58.7 M $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
1.1 B $ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
149 M $ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
45.6 M $ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
126 M - - $ 1.2 B usaUSA
CohBar CohBar
CWBR
16.4 M - -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
4.09 M - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
4.09 M - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
474 M - - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
1.37 B $ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
31.7 M $ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
40.9 M - - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
10.6 M - 7.55 % $ 38.1 M usaUSA